Bill Ackman Backs Mark Cuban's Drug Pricing Model: These Healthcare Stocks Could Win—Or Lose
Bill Ackman backed Mark Cuban's drug pricing model. Here's which healthcare stocks could benefit—and which face pressure.
Stocks · News reference
JP Morgan Maintains Neutral on Humana, Raises Price Target to $393
JP Morgan analyst Lisa Gill maintains Humana (NYSE:HUM) with a Neutral and raises the price target from $316 to $393.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Oil Surges, Treasury Yields Climb a Fifth Day, Software Retreats: Stock Market Today
The 10-year Treasury yield hit a 19-month high and crude jumped above $88 as traders lifted Fed rate-hike odds to 68%, cracking high-multiple software stocks.
Humana Reiterates FY26 Adjusted EPS Outlook Of At Least $9
https://www.sec.gov/ix?doc=/Archives/edgar/data/0000049071/000004907126000052/hum-20260901.htm
8-K filing — HUMANA INC (HUM)
Filed: 2026-09-01 AccNo: 0000049071-26-000052 Size: 150 KB Item 7.01: Regulation FD Disclosure